Liminal BioSciences — Investor Presentation (June 2023)
33 slides from Liminal BioSciences's investor presentation, Jun 2, 2023
Slide 1: GPCR Drug Development Seeking Co-Development Partners
GPCR DRUG DEVELOPMENT INVOLVING CHALLENGING, HIGH-VALUE TARGETS SEEKING GLOBAL & REGIONAL CO-DEVELOPMENT PARTNERS TO ACCELERATE THE PATH TO MARKET JUNE 2023 NASDAQ: LMNL
Slide 2: Forward-looking information
Forward–looking information includes statements concerning, among other things: advancement of Liminal Biosciences' candidates or development programs, including the timing and outcome of the potential development of the Company's R&D programs such as the development of LMNL6511, LMNL6326 and our GP
Slide 3: Why partner with Liminal?
Why partner with liminal? Novel therapeutic candidates designed for high-value GPCR targets Innovation & Leadership in the sought-after field of G Protein-Coupled Receptors (GPCRs) Developing drug candidates for difficult targets of high value (‘undruggable’) Validated target engagement & activity;
Slide 4: GPCR Molecular Target Opportunities
GPCR MOLECULAR TARGET OPPORTUNITIES ~400 GPCR targets active in diseases2 GPCRs ARE COMPELLING TARGETS FOR THERAPEUTIC DEVELOPMENT ~34% of FDA approvals target GPCRs1 Sources: 1 “Unexplored opportunities in the druggable human genome”, Nature Reviews, 2016 ; 2 “Trends in GPCR in Drug Discovery – new
Slide 5: GPCR pipeline focuses on chronic disease, high-value markets
Lmnl’s gpcr pipeline focuses on Chronic Disease, high-value markets 1Centers of Disease Control and Prevention, March 2020 (NHANES, 2021); 2BioSpace, Inc. (syndicated report), July 2021; 3Younossi, Z, et al. Journ of Hepatol 2019;71:793-801; 4Global Industry Analysts, Inc. (syndicated report), Octob
Slide 6: GPCR Drug Discovery pipeline features novel targets
GPCR Drug Discovery pipeline features novel targets Small molecule pipeline targeting metabolic, inflammatory and fibrotic diseases. Global Rights Program Potential Indications Preclinical Clinical Key Milestones Discovery Lead Optimisation CTA-enabling Phase 1 Phase 2 Phase 3 GPR84 Antagonist IBD N
Slide 7: GPR84: broad therapeutic area potential
GPR84: broad therapeutic area potential, with multi-tissue involvement GPR84 is a pro-inflammatory G protein-coupled receptor (GPCR) mainly expressed in neutrophils, monocytes, macrophages and other innate immune cells in the peripheral system, and microglial cells in the nervous central system. GPR
Slide 8: LMNL6511 GPR84 Antagonist Program
LMNL6511 GPR84 Antagonist Program
Slide 9: GPR84: A pivotal role in inflammation and fibrosis
GPR84: A PIVOTAL ROLE IN INFLAMMATION AND FIBROSIS Primarily expressed in immune cells, such as neutrophils, monocytes, and macrophages Abundant in multiple organ systems: heart, lung, kidney, liver, GI tract, CNS and bone marrow.1 WHAT IS THE GPR84 RECEPTOR? GPR84 antagonism is anticipated to addre
Slide 10: GPR84 antagonists: Open Development Landscape for LMNL6511
GPR84 antagonists: Open Development Landscape for LMNL6511 Few Competitive Programs; one clinical program for Neuropathic Pain Labéguère et al., 2020; Mahindra et al., 2022; Chen et al., 2022 GLPG1205 - halted (and related dihydropyrimidino isoquinolinone compounds) BGT-004 (and related phosphodiest
Slide 11: LMNL6511: Candidate Selection & Development Rationale
LMNL6511: Candidate Selection & Development Rationale Liminal’s potent and selective GPR84 antagonist has IP and patent filings for the treatment of inflammatory/fibrotic/metabolic diseases, including NAFLD/NASH and IBD/UC. > 1700 compounds synthesized & tested; LMNL6511 was screened for greater pot
Slide 12: PK/potency of GLPG1205 vs potency of LMNL6511
PK/potency of GLPG1205 vs potency of LMNL6511 Results from GLPG1205 Phase 1 study (Timmis et al., 2021; adapted from Figure 2) vs in vitro potency IC50 and IC90 were established internally using the human GPR84 trafficking to early endosomes assay Taking into consideration the higher potency observe
Slide 13: GLPG1205 Reported Clinical Safety and Tolerability
GLPG1205 Reported Clinical Safety and Tolerability Phase 1 study (Clinicaltrials.gov number NCT01887106; Timmis et al., 2021) Randomized, double-blind, placebo-controlled study of GLPG1205 (part 1: SAD GLPG1205 10 to 800 mg; part 2: MAD GLPG1205 50, 100, or 200 mg once daily for 14 days). Reduced to
Slide 14: Insights from LMNL NASH liver disease in-vivo studies
Results suggests that treatment with a small molecule GPR84 antagonist for 6 weeks could improve liver fibrosis and health in a model of diet-induced liver disease (high fat diet). Treated mice have shown: reduced ALT concentration in the serum reduced liver hypertrophy reduced steatosis as well as
Slide 15: Key take-aways from LMNL IBD in vivo studies
LMNL6511 was evaluated in the indomethacin-induced inflammatory bowel disease rat model. Results showed a reduction in the number of indomethacin-induced lesions and macroscopic disease grade in rats dosed with LMNL6511. We also showed an improvement in the albuminemia (indicating reduction in gut b
Slide 16: GPCR partnerships
GPCR partnerships COMPANIES INDICATIONS STAGE OF ASSETS AT TIME OF PARTNERSHIP COLLABORATION GOALS Tempero Bio & Sosei Heptares Neurological & Psychiatric Disorders Phase 1 Develop potent, orally available mGluR5 negative allosteric modulators. Lead compound TMP-301 (HTL0014242) was designed by Sose
Slide 17: Liminal's partnering approach & timeline
LIMINAL’S PARTNERING APPROACH & TIMELINE Opportunity to secure an option & license agreement for a novel, Phase 1 asset with potential to address unmet need in metabolic, inflammatory & fibrotic-driven diseases; >10% CAGR by 20301,2 Unencumbered competitive landscape: few groups working on GPR84, ma
Slide 18: LMNL6326 OXER1 Antagonist Program
LMNL6326 OXER1 Antagonist Program
Slide 19: OXER1 Potential To Treat Eosinophilic-Driven Disease
OXER1 Potential To Treat Eosinophilic-Driven Disease Gastrointestinal Diseases Respiratory Diseases Other Diseases Skin Diseases Eosinophils are involved in acute and chronic inflammation and play an important role in a large number of allergic, inflammatory and proliferative diseases. Both eosinoph
Slide 20: OXER1 role in asthma
OXER1 ROLE IN Disease is Driven By Eosinophilic Immune Dysfunction Asthma is a heterogeneous disease; there are multiple clinical sub-types The two primary asthma phenotypes, Type 2 high and Type 2 low, are defined by eosinophilic and neutrophilic pattern of inflammation, respectively The Type 2 hig
Slide 21: Eosinophilic and severe asthma markets
EOSINOPHILIC AND SEVERE ASTHMA MARKETS MAY PROVIDE MORE POTENTIAL COMMERCIAL OPPORTUNITY FOR EFFECTIVE, TARGETED THERAPIES $1.3B 2021 SALES est. $2.2B in peak sales (’27)3 9 Approved Products: 5 Topical, 2 Oral and 2 injection2 $1.6B 2021 SALES est. $2.6B in peak sales (‘27)3 Market expected to reac
Slide 22: OXER1 role in atopic dermatitis
OXER1 ROLE IN Disease is Driven By Eosinophilic Immune Dysfunction The immune response observed during the course of Atopic Dermatitis (AD) is characterized by a biphasic inflammation. A Th2-biased immune response (IL-4, IL-13, TSLP and eosinophils) is predominant in the initial and acute phase of A
Slide 23: No other OXER-1 antagonists in development in atopic dermatitis market
NO OTHER OXER-1 ANTAGONISTS IN DEVELOPMENT IN LARGE AND GROWING GLOBAL ATOPIC DERMATITIS MARKET 1 Future Market Insights, Atopic Dermatitis Market Forecast 2021-2029, 2 FDA Centerwatch Approved Drug listing in Atopic Dermatitis, 3Company Website’s, Dupixent indicated in eosinophilic esophagitis, eos
Slide 24: OXER1 antagonist Candidate Selection & Development Rationale
OXER1 antagonist Candidate Selection & Development Rationale Liminal’s potent and selective OXER1 antagonist has IP and patent filings for the treatment of inflammatory, allergic, and proliferative diseases involving eosinophils and neutrophils. An OXER1 antagonist was found to have positive effects
Slide 25: OXER1 antagonist with potential numerous clinical applications
1Dagmar, et al. Current reviews of allergy and clinical immunology. Eosinophilic disorders. 2007. American Academy of Allergy, Asthma & Immunology doi:10.1016/j.jaci.2007.02.010 TARGET Receptor for inflammatory mediator 5-oxo-ETE RATIONALE Blocks potent proinflammatory mediator on eosinophils1 LIMIN
Slide 26: OXER1: Role in tissue repair and inflammation
OXER1: ROLE IN TISSUE REPAIR AND INFLAMMATION OXER1 is a GPCR receptor which is mainly expressed in inflammatory cells. OXER1 is highly selective for 5-oxo-ETE, one of the most powerful chemo-attractants and activators of eosinophils. WHAT IS THE OXER1 RECEPTOR? Eosinophils are involved in acute and
Slide 27: GPR40 Agonist Program
Liminal BioSciences P GPR40 AGONIST PROGRAM © 2023 Liminal BioSciences Inc.
Slide 28: GPR40: Role in metabolic syndrome and glucose management
GPR40: ROLE IN METABOLIC SYNDROME AND GLUCOSE MANAGEMENT GPR40, also known as FFA1 or FFAR1, is a GPCR highly expressed in pancreatic β-cells and responds to medium and long chain unsaturated fatty acids, resulting in increased insulin secretion only in the presence of elevated glucose levels. WHAT
Slide 29: GPR40/FFAR1 Agonists: An Emerging Class of Compounds for T2D
GPR40/FFAR1 Agonists: An Emerging Class OF COMPOUNDS for T2D GPR40 is a validated target for the treatment of Type 2 Diabetes Strong clinical evidence that GPR40 agonists can improve glucose control, without the risk of hypoglycemia. Liver toxicity led to the discontinuation of the most advanced cli
Slide 30: Development Activities & Leadership
30 © 2023 Liminal BioSciences Inc. DEVELOPMENT ACTIVITIES & LEADERSHIP
Slide 31: Data driven execution and delivery
DATA DRIVEN EXECUTION AND DELIVERY H1 2023 On-going In-vivo experiments expected to allow narrow down a lead clinical indication 2023 Ongoing CTA-enabling studies for first-in-human clinical trial H2 2023 Expect to file CTA for first-in-human Phase 1 clinical trial H2 2023 Expect to Commence first-i
Slide 32: Management team with track record of success
MANAGEMENT TEAM WITH TRACK RECORD OF SUCCESS BRUCE PRITCHARD Chief Executive Officer NICOLE RUSAW Chief Financial Officer Marie Iskra General Counsel & Secretary DR. GARY BRIDGER Board Member and Interim Chief Scientific Officer Patrick Sartore President LMNL is led by a strong, experienced team wit
Slide 33: Board of directors
BOARD of directors Alek Krstajic Director Neil A. Klompas Chair Audit, Risk & Finance Committee Simon G. Best (OBE) Chair, Human Resources & Corporate Governance Committee Timothy S. Wach Director DR. GARY BRIDGER Director Eugene Siklos Director As former Chief Executive Officer of Wind Mobile, Alek
Liminal BioSciences — Investor Presentation (June 2023) on 6ix